Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS)

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513105-31-00

Enrollment

440

Registered

2024-07-30

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Brief summary

Radiological disease activity (new/enlarging T2 lesions on brain MRI) after two years

Interventions

DRUGTysabri 300 mg concentrate for solution for infusion

DRUGTyruko 300 mg concentrate for solution for infusion

DRUGTysabri 150 mg solution for injection in pre-filled syringe

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Radiological disease activity (new/enlarging T2 lesions on brain MRI) after two years	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026